...
首页> 外文期刊>BMC Cancer >A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy
【24h】

A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy

机译:非手术治疗后α-胎蛋白阴性肝癌患者伴随卢斯COX回归的预后载体

获取原文
           

摘要

Alpha-fetoprotein-negative hepatocellular carcinoma (AFP-NHCC) (?8.78?ng/mL) have special clinicopathologic characteristics and prognosis. The aim of this study was to apply a new method to establish and validate a new model for predicting the prognosis of patients with AFP-NHCC. A total of 410 AFP-negative patients with clinical diagnosed with HCC following non-surgical therapy as a primary cohort; 148 patients with AFP-NHCC following non-surgical therapy as an independent validation cohort. In primary cohort, independent factors for overall survival (OS) by LASSO Cox regression were all contained into the nomogram1; by Forward Stepwise Cox regression were all contained into the nomogram2. Nomograms performance and discriminative power were assessed with concordance index (C-index) values, area under curve (AUC), Calibration curve and decision curve analyses (DCA). The results were validated in the validation cohort. The C-index of nomogram1was 0.708 (95%CI: 0.673–0.743), which was superior to nomogram2 (0.706) and traditional modes (0.606–0.629). The AUC of nomogram1 was 0.736 (95%CI: 0.690–0.778). In the validation cohort, the nomogram1 still gave good discrimination (C-index: 0.752, 95%CI: 0.691–0.813; AUC: 0.784, 95%CI: 0.709–0.847). The calibration curve for probability of OS showed good homogeneity between prediction by nomogram1 and actual observation. DCA demonstrated that nomogram1 was clinically useful. Moreover, patients were divided into three distinct risk groups for OS by the nomogram1: low-risk group, middle-risk group and high-risk group, respectively. Novel nomogram based on LASSO Cox regression presents more accurate and useful prognostic prediction for patients with AFP-NHCC following non-surgical therapy. This model could help patients with AFP-NHCC following non-surgical therapy facilitate a personalized prognostic evaluation.
机译:α-胎儿蛋白阴性肝细胞癌(AFP-NHCC)(AFP-NHCC)(&α.8.78?Ng / ml)具有特殊的临床病理特征和预后。本研究的目的是应用一种新方法来建立和验证预测AFP-NHCC患者预后的新模型。共有410例AFP阴性患者临床诊断,非手术治疗后的HCC作为主要队列;非手术治疗后148例AFP-NHCC作为独立验证队列。在初级队列中,卢斯考克索回归的整体生存(OS)的独立因素都包含在纳米图中;向前逐步COX回归均包含在墨顶2中。用一致性指数(C折射率)值,曲线(AUC)区域(AUC),校准曲线和判定曲线分析(DCA)评估载体性能和鉴别权。结果在验证队列中验证。 NOMAGRAM1WAS 0.708(95%CI:0.673-0.743)的C折射率优于NOMACHAG2(0.706)和传统模式(0.606-0.629)。墨龛1的AUC为0.736(95%CI:0.690-0.778)。在验证队列中,NOMAGARAM1仍然发出了良好的歧视(C-INDEX:0.752,95%CI:0.691-0.813; AUC:0.784,95%CI:0.709-0.847)。校准曲线对于OS的概率显示在通过NOMARAM1的预测和实际观察之间的良好均匀性。 DCA展示了NOMACH1在临床上有用。此外,患者分别分为题表1:低风险群,中非风险组和高风险组的三种不同的风险群。基于套索COX回归的新型拓图为非手术治疗后AFP-NHCC患者提供更准确和有用的预测预测。该模型可以帮助患有非手术治疗后AFP-NHCC的患者促进个性化的预后评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号